MicroPort® NeuroTech NUMEN Coil Embolization System Approved for Market in China for the treatment of cerebral aneurysms

Shanghai, China—[Monday 19 October 2020] – Shanghai MicroPort NeuroTech Co., Ltd. (“MicroPort® NeuroTech”) recently received the registration certificates issued by China’s National Medical Products Administration (NMPA) for its proprietary NUMEN Coil Embolization System and NUMEN FR Coil Detachment System for the treatment of cerebral aneurysms (also known as brain aneurysms) through minimally invasive neurovascular intervention.

Cases of cerebral aneurysms in China have been gradually increasing in recent years. Statistics show that about three out of every 100 people in China develop cerebral aneurysms.[1] Due to their small size and common occurrence in the neurovascular arteries, cerebral aneurysms are often asymptomatic until ruptures occur. However, they are known as “a ticking time bomb in the body” due to their high mortality and morbidity rate upon rupture.[2]

Treatment options for cerebral aneurysms currently include intracranial aneurysm clipping and neurovascular intervention involving embolization to cut off the flow of blood to the aneurysm. This traditional intracranial aneurysm clipping requires opening the patient’s skull, a procedure known as a craniotomy. This procedure has many shortcomings including; invasiveness, excessive bleeding, long treatment duration, and complications with healing, among others.[3] With neurovascular intervention, on the other hand, it is possible to occlude flow to the aneurysm with micro coils or other embolic materials through a minimally invasive treatment, thereby avoiding the risks of a craniotomy.

The approved NUMEN Coil Embolization System by MicroPort® NeuroTech is available in different lengths, allowing physicians to select the most appropriate coil based on each patient’s anatomy. The NUMEN FR Coil Detachment System is used to provide the electric current needed to detach the coil once in position.

“Coil Embolization is a crucial treatment option for patients with intracranial aneurysms. The approval of the NUMEN Coil Embolization System takes us one step closer to our goal of becoming a ‘total solution provider for stroke treatment’ and we are pleased to provide this minimally invasive treatment option for patients,” said Zhiyong Xie, President of MicroPort® NeuroTech.

The approval of the NUMEN Coil Embolization System and the NUMEN FR Coil Detachment System


[1] Shang Wei, Zhou Hang, Xu Yousong, et al. Research progress in the pathogenesis of intracranial aneurysms. Chinese Journal of Postgraduates of Medicine, 2019,42( 9 ): 846-850. DOI: 10.3760/cma.j. issn.1673-4904.2019.09.021

[2] Christopher S. Eddleman, Christopher C. Getch, Bernard R. Bendok, et al. Chapter 13 – Intracranial Aneurysms. Principles of Neurological Surgery (Third Edition), 2012. DOI: 10.1016/B978-1-4377-0701-4.00013-0

[3] Guo Jiwei. Clinical comparison of intravascular intervention and traditional craniotomy in the treatment of intracranial aneurysms. Nerve Injury and Functional Reconstruction, 2015. Accessed from http://www.cqvip.com/QK/94899A/201504/665609567.html, October 2020